ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
NCT01621269 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2017-04-20
Summary
Study to evaluate efficacy of fingolimod in patients with neutralizing antibodies over 12 months
Conditions
Interventions
- DRUG
-
Fingolimod
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-06-30
- Primary Completion
- 2014-06-30
- Completion
- 2014-06-30
More Related Trials
-
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
NCT04667949 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
NCT02048072 ·Status: COMPLETED ·Phase: PHASE4
-
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
NCT01281657 ·Status: COMPLETED
-
Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
NCT02225977 ·Status: COMPLETED
-
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
NCT01623596 ·Status: COMPLETED ·Phase: PHASE4
-
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
NCT01633112 ·Status: TERMINATED ·Phase: PHASE3
-
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
NCT01199861 ·Status: COMPLETED ·Phase: PHASE3
-
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
NCT01790269 ·Status: TERMINATED
-
Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)
NCT02408380 ·Status: UNKNOWN
-
A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis
NCT01811290 ·Status: UNKNOWN
-
Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM
NCT05684016 ·Status: COMPLETED ·Phase: NA
-
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
NCT03257358 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
NCT00340834 ·Status: COMPLETED ·Phase: PHASE3
-
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®
NCT01705236 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
NCT04480853 ·Status: RECRUITING ·Phase: PHASE4
-
Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
NCT01755871 ·Status: TERMINATED ·Phase: PHASE4
-
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT01310166 ·Status: COMPLETED ·Phase: PHASE4
-
A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis
NCT00288990 ·Status: COMPLETED
-
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
NCT05242133 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT00289978 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Fingolimod Adherence on Outcomes
NCT05141669 ·Status: COMPLETED
-
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT00662649 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
NCT05423769 ·Status: COMPLETED
-
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT01497262 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
NCT01498887 ·Status: COMPLETED ·Phase: PHASE4